Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 109
Appendix B
Speaker, Moderator, and
Panelist Biographies
Amy P. Abernethy, M.D., is a tenured associate professor in the Duke
University Schools of Medicine and Nursing, director of the Duke Cancer
Care Research Program, and a medical oncologist and palliative medicine
physician. She is an appointee to the Institute of Medicine's (IOM's)
National Cancer Policy Forum, president-elect of the American Academy of
Hospice & Palliative Medicine, a member of the board of directors for the
Personalized Medicine Coalition and of the Advisory Board for the Rapid
Learning System for Cancer for the American Society of Clinical Oncology,
and co-chair of the National Institutes of Health (NIH)funded Palliative
Care Research Cooperative Group. Dr. Abernethy participates integrally
in international discussions about reforming the evidence development
system, presenting a model for rapid learning health care by coordinating
clinical and research functions to better serve patients' needs in an evidence-
driven, cost-effective, and patient-centered manner.
Dr. Abernethy is an internationally recognized expert in health services
research and delivery in patient-centered cancer care. She directs the Duke
Cancer Care Research Program, which conducts patient-centered clinical
trials, analyses, and policy studies. The Duke Cancer Care Research Pro-
gram maintains a large portfolio of NIH, National Cancer Institute (NCI),
Agency for Healthcare Research and Quality (AHRQ), philanthropic, and
private funding. All studies make use of, and simultaneously contribute
to the development of, an integrated data system that coordinates diverse
109
OCR for page 110
110 INFORMATICS NEEDS AND CHALLENGES IN CANCER RESEARCH
datasets, leverages novel information technology for patient reporting
of symptoms and other concerns, informs future studies, and facilitates
patient education and patientprovider communication. Dr. Abernethy is
coprincipal investigator (PI) of the NIH-funded Palliative Care Research
Cooperative Group and co-PI of an NCI-funded faculty development
(K01) program in comparative effectiveness research to develop the research
workforce of the future.
Asif Ahmad, M.B.A., M.S., joined US Oncology, now a part of M cKesson
Specialty Health, in 2010 as the executive vice president, Technology Ser-
vices. He currently manages Information and Technology Services, where he
is responsible for leading the development and evolution of strategy related
to information technology (IT) and the company's several IT-based busi-
nesses and services.
Mr. Ahmad served as vice president, Diagnostic Service, and chief
information officer and associate dean, Academic Computing and Imaging,
School of Medicine at Duke University Health System and Medical Center
from 2003 to 2010. Prior to that, he was administrator and chief informa-
tion officer at the Ohio State University Health System and Medical Center.
He earned an M.B.A. at Max M. Fisher College of Business and an M.S. in
biomedical engineering at the Ohio State University. He received his B.S.
(honors) in electrical engineering from the University of Engineering and
Technology in Lahore, Pakistan.
Sam Butler, M.D., brings a wealth of knowledge to Epic's Clinical Infor-
matics Team, with 8 years of senior-level experience in multispecialty medi-
cal group management, along with 14 years of clinical practice experience.
He helps to guide the direction of Epic's applications. He is heavily involved
in the creation and development of Epic and third-party content for use in
clinical applications. Dr. Butler has a B.S. in interdisciplinary science and
received his M.D. from the University of Florida.
Atul Butte, M.D., Ph.D., is chief of the Division of Systems Medicine and
associate professor (tenured) of pediatrics and, by courtesy, m edicine
and computer science, at Stanford University and Lucile Packard Chil-
dren's Hospital. Dr. Butte trained in computer science at Brown University,
worked as a software engineer at Apple and Microsoft, received his M.D.
from Brown University, trained in pediatrics and pediatric endocrinology at
Children's Hospital Boston, and received his Ph.D. in health sciences and
OCR for page 111
APPENDIX B 111
technology from Harvard Medical School and the Massachusetts Institute
of Technology (MIT). He has authored more than 110 publications, deliv-
ered more than 120 invited presentations, and received a number of awards,
including the Society for Pediatric Research Young Investigator Award,
induction into the American College of Medical Informatics, the American
Medical Information Association (AMIA) New Investigator Award, the
Howard Hughes Medical Institute (HHMI) Early Career Award, and the
Pharmaceutical Research and Manufacturers of America (PhRMA) Founda-
tion Research Starter Grant in Informatics. Dr. Butte coauthored one of the
first books on microarray analysis, Microarrays for an Integrative Genomics,
published by MIT Press.
The Butte Laboratory, funded by HHMI and 16 NIH grants, builds
and applies tools that convert more than 300 billion points of molecular,
clinical, and epidemiological data--measured by researchers and clinicians
over the past decade--into diagnostics, therapeutics, and new insights
into disease. The Butte Lab has developed tools to index and find genomic
datasets based on the phenotypic and contextual details of each experi-
ment, to remap microarray data, to deconvolve multicellular samples, and
to perform these calculations on the Internet "cloud." The Butte Lab has
used these tools on publicly available molecular data to successfully find
new uses for existing drugs and has also been developing novel methods for
comparing clinical data from electronic health record (EHR) systems with
gene expression data.
August Calhoun, Ph.D., leads the Dell Healthcare and Life Sciences busi-
ness. The group is responsible for delivering services-based solutions to
hospitals, payers, physicians, life sciences companies, and other key players
in the health care industry. In this role, Dr. Calhoun oversees global strategy,
executive leadership, operations, and business development.
Dr. Calhoun has more than 15 years of experience in the health care
and life sciences industry, during which time he has focused on research
productivity, life sciences sales force effectiveness, translational medicine,
and health care outcomes management. He has expertise in data manage-
ment, technology strategy, high-performance computing, and process
improvement.
Prior to his current role, Dr. Calhoun was responsible for sales and
business development of the Dell Healthcare and Life Sciences industry
team, where he led efforts to implement innovative solutions to automate
operations for health care payers, providers, and life sciences customers.
OCR for page 112
112 INFORMATICS NEEDS AND CHALLENGES IN CANCER RESEARCH
He has also served Dell customers through end user services optimiza-
tion, service desk improvement, asset utilization, and remote data center
operations.
Prior to joining Dell, Dr. Calhoun worked at the IBM Corporation,
where he managed the global pharmaceutical sales and solutions team, as
well as a health care consulting team. He was also responsible for relation-
ships with large health care and life sciences clients and held earlier positions
in IBM Global Services.
Dr. Calhoun has a Ph.D. in physical chemistry from the University of
Pennsylvania in Philadelphia and a B.S. in chemistry from the University
of Delaware in Newark.
James Cimino, M.D., is chief of the Laboratory for Informatics Develop-
ment at the NIH Clinical Center, a senior scientist at the National Library
of Medicine (NLM), and an adjunct professor in biomedical informatics at
Columbia University. He is charged with the development of an institute-
wide Biomedical Translational Research Information System (BTRIS)
and conducts clinical informatics research. Dr. Cimino has been an active
member of the NLM Board of Scientific Counselors, co-chair of the HL-7
Vocabulary Technical Committee, and a member of the board of the Ameri-
can Medical Informatics Association. He is a fellow of the American College
of Medical Informatics, the American College of Physicians, the American
Clinical and Climatologic Association, and the New York Academy of
Medicine and has received a number of awards.
Previously, Dr. Cimino was with the Center for Medical Informatics
(now the Department of Biomedical Informatics) at Columbia Univer-
sity College of Physicians and Surgeons, where he conducted informatics
research, built clinical information systems, taught informatics and medi-
cine, and practiced general internal medicine. He published landmark work
on controlled terminologies (including a widely adopted set of "desiderata"),
the Unified Medical Language System, the use of the Internet in health care,
patient access to personal health records, studies of clinician information
needs, and development of the "infobutton."
Dr. Cimino received a degree in computers in the biomedical sci-
ences at Brown University and an M.D. at New York Medical College. He
completed his medical internship and residency at Saint Vincent's Hospi-
tal in New York and an NLM-sponsored research fellowship in medical
informatics at Massachusetts General Hospital and the Harvard School of
Public Health.
OCR for page 113
APPENDIX B 113
Adam M. Clark, Ph.D., is a patient advocacy consultant and founder,
MedTran Health Strategies. Previously, he was a program officer program
officer in the Division of Strategic Science and Technology for the Bio-
medical Advanced Research and Development Authority within the U.S.
Department of Health and Human Services (HHS) Office of the Assistant
Secretary for Preparedness & Response. In this position he administers
drug, diagnostic, and medical technology development programs aimed at
advancing medical countermeasures to protect the public health.
Previously, Dr. Clark has worked with numerous patient advocacy and
disease research organizations including LIVESTRONG, a cancer research
advocacy organization founded by Lance Armstrong, where he served as
director of science and health policy. Prior to his work at the foundation, he
served as a technology development specialist at NCI, developing programs
in cancer biomarker detection technologies. In his time at NCI, Dr. Clark
also performed assignments in the White House Office of Science and
Technology Policy and the Office of the Secretary of HHS. Dr. Clark has a
background in biomedical sciences as a researcher, program administrator,
and policy adviser with a focus on molecular diagnostics and personalized
medicine.
Dr. Clark has served on several committees and advisory boards,
including the Federal Advisory Committee for Health Information Tech-
nology Policy at HHS and the NCI Director's Consumer Liaison Group.
He earned his Ph.D. from the University of Cincinnati College of Medicine
and was trained in science and health policy through the Emerging Leaders
Program at HHS.
Robert L. Comis, M.D., is president and chair of the Coalition of Cancer
Cooperative Groups (the coalition); group chair of the Eastern Cooperative
Oncology Group (ECOG); and professor of medicine and director of the
Drexel University Clinical Trials Research Center. A leader in international
clinical trials research since 1977, Dr. Comis also serves as president of the
ECOG Research and Education Foundation; president of Alpha Oncology,
a coalition clinical research division; and chair of ITA Partners.
Dr. Comis is a champion of patient access to cancer clinical trials,
spearheading multiple initiatives to raise awareness about the pivotal role of
cancer clinical trials in cancer prevention, detection, and treatment. He is
a current member of the board of directors for C-Change and the National
Coalition for Cancer Research, as well as a past board member of the Ameri-
can Society of Clinical Oncology (ASCO), where he served on a number of
OCR for page 114
114 INFORMATICS NEEDS AND CHALLENGES IN CANCER RESEARCH
ASCO committees. While chairing the Group Chairs for the Cooperative
Group Program, he raised the international profile of the program and initi-
ated efforts to strengthen and reposition it for the future. He has served on a
number of editorial boards, authored more than 140 scientific articles, and
contributed to more than 20 scientific and medical textbooks on cancer.
Dr. Comis is sought as a subject matter expert to the U.S. Congress, the
IOM, President's Cancer Panel, National Cancer Advisory Board, and many
other national and international organizations.
A graduate of Fordham University, Dr. Comis received his medical
degree from the State University of New York (SUNY) Health Science
Center School of Medicine, where he also completed his medical internship
and residency. He served as a staff associate at NCI and completed a medical
oncology fellowship at the Sidney Farber Cancer Center at Harvard Medi-
cal School. He has held clinical practice and research leadership positions at
Thomas J efferson University Hospital, Temple University School of Medi-
cine, Fox Chase Cancer Center, and Allegheny Cancer Center. Dr. Comis is
a diplomate of the American Board of Internal Medicine and a member of
the American College of PhysiciansAmerican Society of Internal Medicine.
William S. Dalton, Ph.D., M.D., is CEO of M2Gen, a national biotech-
nology subsidiary of Moffitt Cancer Center. Until July 2012, Dr. Dalton
served as president, CEO, and center director of Moffitt Cancer Center &
Research Institute. A nationally renowned cancer researcher, physician, and
health policy expert, Dr. Dalton has dedicated his career to the study and
development of the most effective approaches to cancer research and care.
Dr. Dalton currently serves as the president of the Association of
American Cancer Institutes and is chair of the Science Policy & Legisla-
tive Affairs Committee of the American Association for Cancer Research
(AACR). In addition, he has served on the NCI Board of Scientific Advisors
as well as multiple scientific advisory boards at cancer centers and research
foundations.
Dr. Dalton is also interested in the development of personalized cancer
care and patient-centered outcomes research. Moffitt's Total Cancer Care
is an approach to enhance access to evidence-based, personalized cancer
treatments and information or decision tools for patients and clinicians.
Total Cancer Care is one of the largest cancer tumor biorepositories and
data warehouses in the United States dedicated to use in the development
of personalized medicine.
OCR for page 115
APPENDIX B 115
Dr. Dalton received his Ph.D. in toxicology and medical life sciences and
his M.D. from Indiana University. He completed his internship in internal
medicine at Indiana University and his residency in medicine and fellowships
in oncology and clinical pharmacology at the University of Arizona. Prior to
accepting the position as CEO and center director at Moffitt, Dr. Dalton was
the dean of the College of Medicine at the University of Arizona.
Gwen Darien, a cancer survivor herself, brings a wealth of personal and
professional experiences to her position as a director of The Pathways
Project, an organization that creates radically inclusive, accessible com-
munities that put people at the center of health care. Ms. Darien served
as executive director of the Samuel Waxman Cancer Research Foundation
(SWCRF). In this role, she was committed to developing collaborations
across all segments of the cancer community to translate cancer research
discoveries from the bench to the clinic.
Prior to joining SWCRF, Ms. Darien was editor-in-chief of CR maga-
zine and founding director of the American Association for Cancer Research
Survivor and Patient Advocacy Program, where she led initiatives to foster
mutually beneficial and enduring partnerships among leaders of the cancer
survivor, patient advocacy, and scientific communities through collabora-
tions, communications, and education. Ms. Darien was previously the
editor-in-chief of MAMM, a consumer magazine dedicated to women with
breast and reproductive cancer. During Ms. Darien's tenure, MAMM won
international acclaim for its coverage of survivorship, health disparities, and
controversies in women's cancers and health care policy.
Ms. Darien is chair of the NCI Director's Consumer Liaison Group. She
is a member of the board of directors of ENACCT (Education Network to
Advance Cancer Clinical Trials) and the Strategic Advisory Group (SAGE)
of the Center for Patient Partnerships at the University of Wisconsin. She
has served on the Secretary's Advisory Committee on Health, Genetics, and
Society and the faculties of the AACR-ASCO Methods in Clinical Cancer
Research Workshop, the Accelerating Anti-cancer Agent Development
and Validation Workshop, and the advisory board of the Health Advocacy
Program at Sarah Lawrence College. She has received several awards for
her work, including the Avon Foundation Media Leadership Award, the
LYMPHAdvocate Award from the Cure for Lymphoma Foundation, and
the Sisters' Network Media Leadership Award. She is a graduate of Sarah
Lawrence College.
OCR for page 116
116 INFORMATICS NEEDS AND CHALLENGES IN CANCER RESEARCH
Lynn Etheredge, an independent consultant on health care and social
policy issues, works with the Rapid Learning Project at George Washington
University. His career started at the White House Office of Management
and Budget (OMB). During the Nixon and Ford administrations, he was
OMB's principal analyst for Medicare and Medicaid and led its staff work
on national health insurance proposals. Mr. Etheredge headed OMB's pro-
fessional health staff in the Carter and Reagan administrations. Later, he
was a coauthor of the Jackson Hole Group's proposals for health care reform
and a founding member of the National Academy of Social Insurance. His
recent publications include "Medicare's Future: Cancer Care"; "Medicaid:
A Future Leader in Effective, High-Quality Care" (an open letter with 12
coauthors); "A Rapid-Learning Health System" (Health Affairs special issue);
"Administering a Medicaid + Tax Credits Initiative"; and "Technologies of
Health Policy." He is author of more than 85 publications and is a graduate
of Swarthmore College.
Brandon Hayes-Lattin, M.D., is senior medical adviser for the Lance
Armstrong Foundation, an associate professor of medicine in the Divi-
sion of Hematology and Medical Oncology at Oregon Health & Science
University (OHSU), and the director of the OHSU Knight Cancer Insti-
tute's Adolescent and Young Adult (AYA) Oncology Program. His clinical
background is in the management of hematologic malignancies and the
use of hematopoietic stem cell transplantation. However, as a young adult
cancer survivor himself and a physician caring for many young adults with
hematologic malignancies, Dr. Hayes-Lattin has taken a leadership role in
the development of the discipline of adolescent and young adult oncol-
ogy. He served as the inaugural medical co-chair of the Lance Armstrong
Foundation's LIVESTRONG Young Adult Alliance, a coalition of over
150 member organizations leading efforts to research and serve AYA can-
cer patients. Working in collaboration with the National Cancer Institute,
the LIVESTRONG Young Adult Alliance established the Adolescent and
Young Adult Oncology Progress Review Group, publishing recommenda-
tions and strategic plans for the advancement of AYA Oncology. He cur-
rently writes a blog for LIVESTRONG. Dr. Hayes-Lattin also serves on the
Expert Advisory Panel to the AYA Committee of the Children's Oncology
Group and the Federal Advisory Committee on Breast Cancer in Young
Women, and he advises many advocacy groups on the medical needs of
cancer patients.
OCR for page 117
APPENDIX B 117
Bradford (Brad) Hesse, Ph.D., is chief of the NCI Health Communication
and Informatics Research Branch. For more than two decades, Dr. Hesse
has been conducting research in the interdisciplinary fields of social cogni-
tion, health communication, health informatics, and user- centered design.
He was recruited to NCI in 2003 and has since been focusing on bringing
the power of evidence-based health communication technologies to bear on
the problem of eliminating death and suffering from cancer. He continues
to direct the Health Information National Trends Survey, a biennial general
population survey aimed at monitoring the public's use of health informa-
tion during a period of enhanced capacity at the crest of the information
revolution; he also serves as program director for the Centers of Excellence
in Cancer Communication Research, a cutting-edge research initiative aimed
at expanding the knowledge base underlying effective cancer communication
strategies. Dr. Hesse has authored or coauthored more than 150 publica-
tions, including peer-reviewed journal articles, technical reports, books, and
book chapters. In 2009, his coauthored book entitled Making Data Talk:
Communicating Public Health Data to the Public, Policy Makers, and the Press
was named Book of the Year by the American Journal of Nursing.
Dr. Hesse received his degree in social psychology from the University
of Utah in 1988 with an accompanying internship in the nascent field of
medical informatics and later served as a postdoctoral fellow in the Depart-
ment of Social and Decision Sciences at Carnegie Mellon University.
Leroy Hood, M.D., Ph.D., is president and co-founder of the Institute for
Systems Biology in Seattle. Dr. Hood is a pioneer in systems approaches to
biology and medicine. His research has focused on the study of molecular
immunology, biotechnology, and genomics. His professional career began
at Caltech, where he and his colleagues developed the DNA sequencer and
synthesizer and the protein synthesizer and sequencer--four instruments
that paved the way for the successful mapping of the human genome and
led to his receiving the 2011 prestigious Russ Prize, awarded by the National
Academy of Engineering. A pillar in the biotechnology field, Dr. Hood has
played a role in founding more than 14 biotechnology companies, includ-
ing Amgen, Applied Biosystems, Darwin, The Accelerator, and Integrated
Diagnostics. He is a member of the National Academy of Sciences, the
National Academy of Engineering, and the Institute of Medicine, one of
only 15 people in the world to be elected to all three academies. In addi-
tion to having published more than 700 peer-reviewed articles, he has
coauthored textbooks in biochemistry, immunology, molecular biology,
OCR for page 118
118 INFORMATICS NEEDS AND CHALLENGES IN CANCER RESEARCH
and genetics, as well as a popular book on the human genome project, The
Code of Codes. He is the recipient of numerous awards, including the Lasker
Award, the Kyoto Prize, and the Heinz Award in Technology. Dr. Hood
has also received 17 honorary degrees from prestigious universities in the
United States and other countries and holds 36 patents.
Jason Hwang, M.D., M.B.A., is an internal medicine physician and co-
founder and executive director of Health Care at the Innosight Institute, a
nonprofit social innovation think tank based in Mountain View, Califor-
nia. Together with Professor Clayton M. Christensen of Harvard Business
School and the late Jerome H. Grossman of the Harvard Kennedy School
of Government, he is coauthor of The Innovator's Prescription: A Disruptive
Solution for Health Care, the American College of Healthcare Executives
2010 Book of the Year, and recipient of the 2011 Health Service Journal
Circle Prize for Inspiring Innovation.
Previously, Dr. Hwang taught as chief resident and clinical instructor
at the University of California, Irvine, where he received multiple recogni-
tions for his clinical work. He has also served as a clinician with the South-
ern California Kaiser Permanente Medical Group and the Department of
Veterans Affairs Medical Center in Long Beach, California. Dr. Hwang
received his B.S. and M.D. from the University of Michigan and his M.B.A.
from Harvard Business School.
Kris Joshi, Ph.D., is global vice president for Oracle's health care product
portfolio. Dr. Joshi helped launch the Health Sciences Global Business Unit
within Oracle, and in his prior role as head of Strategy and Operations, he
led the business unit's growth strategy, including the acquisitions of Relsys
and Phase Forward. He oversees a broad product portfolio that covers ana-
lytics, health information exchange, care management, and "convergence"
solutions for personalized medicine and translational research that serve
both health care and life sciences customers.
Dr. Joshi brings deep experience across business and technology strat-
egy, M&A, operations, sales, marketing, and business transformation. Prior
to Oracle, he served in senior strategy roles in IBM's Global Sales and Dis-
tribution Organization, where he helped shape IBM's global distribution
and emerging markets strategies. Prior to IBM, Dr. Joshi spent several years
as a consultant with McKinsey and Company, where he served Fortune 500
clients in the banking, media, health care, and life sciences industries on
business strategy issues.
OCR for page 119
APPENDIX B 119
Dr. Joshi has a long-standing personal commitment to help bridge
the gap between the social and business worlds through entrepreneurship,
innovation, and publicprivate partnerships. He has championed numerous
initiatives aimed at leveraging technology to improve the quality, safety, and
affordability of health care globally.
Dr. Joshi holds a B.S. in mathematics from Caltech and a Ph.D. in
astrophysics from MIT.
Marcia Kean, M.B.A., has built Feinstein Kean Healthcare's national role
in the life sciences since the firm's inception 25 years ago. She served as the
CEO of the firm from 2002 to 2011 and became chair of Strategic Initia-
tives in 2011.
Ms. Kean has more than 35 years of biomedical industry experience,
in support of hundreds of start-ups and publicly traded companies, as well
as large-scale national and international science and technology-driven pro-
grams. She has decades of business operating experience as well as knowl-
edge of the development and implementation of publicprivate projects
undertaken by multistakeholder ecosystems.
In 2003, Ms. Kean founded the first molecular medicine communica-
tions practice in the country. She has served as an adviser to the Personal-
ized Medicine Coalition (PMC) since its inception and was awarded that
organization's first Distinguished Service Award in 2006. She has served
on the planning committee for the HarvardPartners Center for Person-
alized Genetic Medicine annual personalized medicine conference since
its inception. She served in 2006 as a member of the Personalized Health
Care Expert Panel convened by the Office of the Assistant Secretary for
Planning and Evaluation (ASPE) of HHS. She chairs the Advisory Com-
mittee of Turning the Tide Against Cancer Through Sustained Medical
Innovation, a national conference on science and policy co-hosted by
the Personalized Medicine Coalition, American Association for Cancer
Research, and Feinstein Kean Healthcare.
Ms. Kean holds an M.B.A. in finance from New York University and
a B.A. from the University of California, Berkeley.
Kimary Kulig, Ph.D., M.P.H., is vice president of clinical and transla-
tional outcomes research at the National Comprehensive Cancer Network
(NCCN). Her primary responsibility is to direct the ongoing development
and advancement of the NCCN Oncology Outcomes Database (NCCN
Database) and other outcomes research programs. The NCCN Database is
OCR for page 120
120 INFORMATICS NEEDS AND CHALLENGES IN CANCER RESEARCH
a set of databases with comprehensive data, including clinical outcomes, on
five major tumor types for thousands of patients treated at NCCN member
institutions.
Prior to joining NCCN, Dr. Kulig worked for several years leading
outcomes-based research in oncology at Pfizer, Inc., most recently as senior
director and lead, Molecular Epidemiology Research, Oncology. In this
role, she designed and conducted biomarker-linked outcomes research
projects in support of multiple clinical development programs, including
those involving companion diagnostics, at the global level.
Prior to Dr. Kulig's appointment at Pfizer, Inc., she led an epidemiology
and surveillance research program for the Arthritis Foundation, conducted
public health research at the Columbia University Mailman School of Pub-
lic Health and the Centers for Disease Control and Prevention, and engaged
in immunology research at Columbia University's College of Physicians and
Surgeons, the Kennedy Institute of Rheumatology (London), and the Mayo
Clinic (Rochester, Minnesota).
Dr. Kulig holds a master's degree in public health with an emphasis
in epidemiology from the Columbia University Mailman School of Public
Health and earned her doctorate in immunology and molecular oncology
from the New York University School of Medicine.
Mia A. Levy, M.D., Ph.D., is director of cancer clinical informatics for
the Vanderbilt-Ingram Cancer Center and assistant professor of biomedi-
cal informatics and medicine. Dr. Levy received her undergraduate degree
in bioengineering from the University of Pennsylvania in 1997 and her
medical doctorate from Rush University in 2003. She then spent six years
at Stanford University for postgraduate training in internal medicine and
medical oncology while completing her Ph.D. in biomedical informatics.
She joined the faculty at Vanderbilt as an assistant professor of biomedi-
cal informatics and medicine in August 2009. She is a practicing medical
oncologist specializing in the treatment of breast cancer.
Dr. Levy's research interests include biomedical informatics methods
to support the continuum of cancer care and cancer research. Current
research projects include informatics methods for (1) image-based cancer
treatment response assessment using quantitative imaging, (2) clinical
decision support for treatment prioritization of molecular subtypes of
cancer, (3) protocol-based plan management, and (4) learning cancer
systems.
OCR for page 121
APPENDIX B 121
Allen S. Lichter, M.D., is CEO of ASCO, the world's leading professional
organization, representing nearly 30,000 physicians and health profession-
als in oncology.
Prior to joining ASCO in 2006, Dr. Lichter was at the University of
Michigan in two significant leadership roles. He served as chair and profes-
sor of radiation oncology from 1984 to 1998 and as dean of the Medical
School from 1998 to 2006. Dr. Lichter was named the first Isadore Lampe
Professor of Radiation Oncology, an endowed chair, and also was the
Newman Family Professor of Radiation Oncology.
Prior to his tenure at the University of Michigan, Dr. Lichter was direc-
tor of the Radiation Therapy Section of NCI's Radiation Oncology Branch.
Dr. Lichter's research and development of three-dimensional treatment
planning led to a Gold Medal from the American Society for Therapeutic
Radiology and Oncology. In 2002, he was elected to the Institute of Medi-
cine of the National Academies of Sciences.
As a member of ASCO since 1980, Dr. Lichter has assumed many
prominent roles in the Society, including president (19981999) and
founding chair of ASCO's Conquer Cancer Foundation Board.
Dr. Lichter earned a bachelor's degree (1968) and a medical degree
(1972) from the University of Michigan. He trained in radiation oncology
at the University of California, San Francisco, before joining the faculty at
Johns Hopkins University and later NCI.
Daniel R. Masys, M.D., is affiliate professor of biomedical and health
informatics at the University of Washington (UW), Seattle. An honors
graduate of Princeton University and the Ohio State University College of
Medicine, he completed postgraduate training in internal medicine, hema-
tology, and medical oncology at the University of California, San Diego,
and the Naval Regional Medical Center, San Diego. His more than 30-year
career in biomedical informatics prior to joining UW included leadership
positions at NCI and NLM and faculty appointments at the University of
California, San Diego, and the Vanderbilt University School of Medicine,
where he was emeritus professor and chair of the Department of Biomedi-
cal Informatics.
Dr. Masys is an elected member of the Institute of Medicine. He is a
fellow of the American College of Physicians and a fellow and past president
of the American College of Medical Informatics. He was a founding associ-
ate editor of the Journal of the American Medical Informatics Association and
OCR for page 122
122 INFORMATICS NEEDS AND CHALLENGES IN CANCER RESEARCH
has received numerous awards including the NIH Director's Award and the
U.S. Surgeon General's Exemplary Service Medal.
Deven McGraw, J.D., L.L.M., is director of the Health Privacy Project at
the Center for Democracy and Technology (CDT). The project is focused
on developing and promoting workable privacy and security protections for
electronic personal health information.
Ms. McGraw is active in efforts to advance the adoption and imple-
mentation of health information technology and electronic health infor-
mation exchange to improve health care. She was one of three people
appointed by Kathleen Sebelius, secretary of HHS, to serve on the Health
Information Technology (HIT) Policy Committee, a federal advisory com-
mittee established in the American Recovery and Reinvestment Act of
2009. She chairs the Committee's Privacy and Security Workgroup (the
"Tiger Team") and serves as a member of its Meaningful Use and Informa-
tion Exchange Workgroups. She also served on the Policy Steering Com-
mittee of the eHealth Initiative and now serves on its Leadership Council.
She is also on the Steering Group of the Markle Foundation's Connecting
for Health multistakeholder initiative.
Ms. McGraw has a strong background in health care policy. Prior to
joining CDT, she was the chief operating officer of the National Partnership
for Women & Families, providing strategic direction and oversight for all
of the organization's core program areas, including the promotion of initia-
tives to improve health care quality. Ms. McGraw also was an associate in
the public policy group at Patton Boggs, LLP and in the health care group
at Ropes & Gray. She served as deputy legal counsel to the governor of
Massachusetts and taught in the Federal Legislation Clinic at Georgetown
University Law Center.
Ms. McGraw graduated magna cum laude from the University of
Maryland. She earned her J.D., magna cum laude, and her L.L.M. from
Georgetown University Law Center and was executive editor of the
Georgetown Law Journal. She also has a master of public health degree from
the Johns Hopkins Bloomberg School of Hygiene and Public Health.
John Mendelsohn, M.D., was president of the University of Texas M.D.
Anderson Cancer Center in Houston from 1996 until 2011. Under his
direction, M.D. Anderson assumed a leadership role in translational and
clinical cancer research and was named the top cancer hospital in the United
States for 8 of the past 10 years in the U.S. News & World Report "America's
OCR for page 123
APPENDIX B 123
Best Hospitals" survey. Currently, Dr. Mendelsohn is the co-director of the
Khalifa Institute for Personalized Cancer Therapy at M.D. Anderson. Previ-
ously, he chaired the Department of Medicine at Memorial Sloan-Kettering
Cancer Center, and he began his career at the University of California, San
Diego (UCSD), in La Jolla, where he was founding director of its cancer
center. Dr. Mendelsohn and his collaborators pioneered the concept of
therapy to target the products of genes that cause cancer. His team's innova-
tive research on inhibition of the epidermal growth factor (EGF) receptor
tyrosine kinase led to production and investigation of monoclonal antibody
C225 (Erbitux), which is approved by the Food and Drug Administration
(FDA) for colon cancer and head and neck cancer. He served as found-
ing editor-in-chief of Clinical Cancer Research, has published more than
250 articles and reviews, and has received many prizes and awards. Dr.
Mendelsohn is chair of the IOM's National Cancer Policy Forum. He
has directed postdoctoral programs that trained many dozens of medical
oncologists and scientists. He is an active board member of several Houston
area organizations, including the Houston Grand Opera, the BioHouston,
and the Center for Houston's Future.
Farzad Mostashari, M.D., Sc.M., is national coordinator for health
information technology within the Office of the National Coordinator
for Health Information Technology (ONC) at HHS. Farzad joined ONC
in July 2009. Previously, he served at the New York City Department of
Health and Mental Hygiene as assistant commissioner for the Primary
Care Information Project, where he facilitated the adoption of prevention-
oriented health information technology by more than 1,500 providers in
underserved communities. Dr. Mostashari also led the Centers for Disease
Control and Prevention (CDC)funded New York City Center of Excel-
lence in Public Health Informatics and an AHRQ-funded project focused
on quality measurement at the point of care. Prior to this, he established
the Bureau of Epidemiology Services at the New York City Department of
Health, charged with providing epidemiologic and statistical expertise and
data for decision making to the health department.
He completed his graduate training at the Harvard School of P ublic
Health and Yale Medical School, his internal medicine residency at
Massachusetts General Hospital, and completed the CDC's Epidemic
Intelligence Service. He was one of the lead investigators in the outbreaks
of West Nile virus and anthrax in New York City and was among the first
developers of real-time electronic disease surveillance systems nationwide.
OCR for page 124
124 INFORMATICS NEEDS AND CHALLENGES IN CANCER RESEARCH
Spyro Mousses, Ph.D., is professor at the Translational Genomics Research
Institute (TGen), in Phoenix, Arizona. His scientific background and exper-
tise include developing platform genomic and computational technologies
and he recently has focused on strategically integrating multiple technolo-
gies and scientific resources to engineer innovative solutions that can sup-
port drug discovery, translational research, clinical drug development, and
personalized medicine. Toward the goal of integrating technologies across
sectors into unifying solutions, Dr. Mousses has lead multi disciplinary
publicprivate collaborations and developed partnerships with major cor-
porations in the pharmaceutical, biotech, life sciences, and IT industries.
He is also a mission-driven entrepreneur and has served as chief scientific
officer and co-founder of Systems Medicine Inc. (acquired by Cell Thera-
peutics Inc.) and MedTrust OnLine Inc. (acquired by Annai Systems Inc.).
Dr. Mousses received his B.Sc. (pharmacology and toxicology), M.Sc., and
Ph.D. (molecular pathogenesis and genetics of cancer) from the University
of Toronto. He served as staff scientist at the National Human Genome
Research Institute, NIH, where he led a program in cancer genome scan-
ning and high-throughput technology development. He joined TGen at its
inception as one of the founding scientists, contributing to building and
directing the Cancer Drug Development Laboratory and the Pharmaceuti-
cal Genomics Division. Most recently, he was appointed director of the
Center for BioIntelligence and was named vice president in the Office of
Innovation.
Sharon Murphy, M.D., joined the Institute of Medicine as a scholar-
in-residence in October 2008, coming to the District of Columbia from
Texas, where she was inaugural director of the Greehey Children's Cancer
Research Institute and professor of pediatrics at the University of Texas
Health S cience Center at San Antonio from 2002 to 2008.
From 1988 to 2002, Dr. Murphy was chief of the Division of
Hematology-Oncology at Children's Memorial Hospital in Chicago and
professor of pediatrics at Northwestern University School of Medicine,
where she also led the program in pediatric oncology at the Robert H.
Lurie Cancer Center. From 1974 to 1988, Dr. Murphy was on the faculty
at St. Jude Children's Research Hospital in Memphis.
A pediatric oncologist and clinical cancer researcher, Dr. Murphy has
devoted the past 35 years to improving cure rates for childhood cancer,
particularly childhood lymphomas and leukemias. She was chair of the
Pediatric Oncology Group from 1993 to 2001. She has been recognized
OCR for page 125
APPENDIX B 125
for her achievements by the Association of Community Cancer Centers
(2001), the Distinguished Service Award for Scientific Leadership from
ASCO (2005), and the Distinguished Career Award from the American
Society of Pediatric Hematology and Oncology (2009).
The author of more than 220 original articles, reviews, and book
chapters, Dr. Murphy has also served on numerous editorial boards. She has
been a member of the boards of directors of the American Cancer Society,
AACR, the American Society of Hematology, and ASCO, and she has been
an adviser to NCI and FDA.
She earned her bachelor of science degree from the University of
Wisconsin (1965) and her medical degree, cum laude, from Harvard Medi-
cal School (1969). She completed postdoctoral training in pediatrics at the
University of Colorado (19691971) and in pediatric hematology and
oncology at the University of Pennsylvania (19711973).
Steven Piantadosi, M.D., Ph.D., is director of the Samuel Oschin
Comprehensive Cancer Institute at Cedars-Sinai Medical Center.
Dr. Piantadosi's role is to lead the medical center's programs in cancer
research, treatment, and education; enhance academic activities related
to cancer; and bring together Cedars-Sinai's cancer physicians and
researchers for innovative collaborations.
Prior to joining Cedars-Sinai in December 2007, Dr. Piantadosi
was professor of oncology at the Johns Hopkins University School of
Medicine and director of biostatistics at the Sidney Kimmel Compre-
hensive Cancer Center. He also was a professor of biostatistics and of
epidemiology at the Bloomberg School of Public Health. After earning
his medical degree from the University of North Carolina and his doctor-
ate in bio mathematics from the University of Alabama at Birmingham,
Dr. Piantadosi became a senior staff fellow at NCI.
Dr. Piantadosi is one of the world's leading experts in the design and
analysis of clinical trials for cancer research. In addition to advising both
FDA and industry, he has served on external advisory boards for NIH and
other prominent cancer programs and centers.
The author of more than 230 peer-reviewed scientific articles,
Dr. Piantadosi has published extensively on research results, clinical appli-
cations, and trial methodology. While his papers have contributed to many
diverse areas of oncology, he has also collaborated on studies in disciplines
outside cancer including lung disease, AIDS, and degenerative neurologi-
cal disease. Dr. Piantadosi is the author of Clinical Trials: A Methodologic
OCR for page 126
126 INFORMATICS NEEDS AND CHALLENGES IN CANCER RESEARCH
Perspective, which is widely considered a classic textbook for clinical trials.
He has taught young investigators extensively in his own course, the Uni-
versity of California, Los Angeles (UCLA), STAR program, and through
international venues such as the AACR-ASCO Workshop on Methods in
Clinical Cancer Research. Dr. Piantadosi has held leadership roles with
national cooperative oncology groups and has been a member of numerous
clinical trial monitoring committees.
Bradley H. Pollock, M.P.H., Ph.D., is professor and the founding chair
of the Department of Epidemiology and Biostatistics in the School of
Medicine at the University of Texas Health Science Center at San Antonio
(UTHSCSA). He holds adjunct professorships at the University of Texas
School of Public Health, the College of Business at the University of Texas
at San Antonio, and the Department of Statistics at Texas A&M Univer-
sity. In 2001, he started the Center for Epidemiology and Biostatistics at
UTHSCSA, which evolved into the Department of Epidemiology and
Biostatistics in 2006.
Dr. Pollock served as a cooperative group statistician for the Pediatric
Oncology Group (POG) and the successor Children's Oncology Group
(COG). He has been responsible for the biostatistical management of
Phase I through Phase III cancer clinical trials, correlative biology studies,
interventional trials, and numerous observational studies. He has served
continuously as principal investigator of the Community Clinical O ncology
Program (CCOP) Research Base grant for POG and COG since 1995,
chair of the POG Epidemiology Committee from 1991 to 2000, and chair
of the POG and COG Cancer Control Committees from 1995 to 2003.
Dr. Pollock serves as director of the Biostatistics and Informatics Shared
Resource for the P30-funded NCI-designated Cancer Therapy & Research
Center (CTRC). He also directs two cores for the NIH-funded Clinical
& Translational Science Award (CTSA) at UTHSCSA: the Biostatistics,
Epidemiology, and Research Design Core and the Biomedical I nformatics
Core. Dr. Pollock is the current vice chair and chair-elect of the CTSA
Biostatistics/Epidemiology/Research Design Key Function Committee.
In addition, he is president of the Association of Clinical Translational
Statisticians.
Dr. Pollock's research focuses on pediatric and adolescent oncology,
with an emphasis on cancer epidemiology and cancer prevention and
control research. He has served on numerous NIH grant review and other
scientific committees.
OCR for page 127
APPENDIX B 127
Dr. Pollock received his B.S. in biological sciences from the University
of California, Irvine, and his M.P.H. and Ph.D. in epidemiology (minor in
biostatistics) from the UCLA School of Public Health.
George Poste, Ph.D., D.V.M., is chief scientist for the Complex Adaptive
Systems Initiative (http://www.casi.asu.edu) at Arizona State University
(ASU). From 2003 to 2009, he created and built the Biodesign Institute at
ASU (http://www.biodesign.asu.edu).
He serves on the board of directors of Monsanto, Exelixis, and Caris
Life Sciences and the scientific advisory board of Synthetic G
enomics. From
1992 to 1999, he was chief science and technology officer of SmithKline
Beecham. In 2004 he was named R&D Scientist of the Year by R&D
Magazine; in 2006, he received the Einstein award from the Global Business
Leadership Council; and in 2009, he received the Scrip Lifetime Achieve-
ment award.
Dr. Poste is a fellow of the Royal Society (UK), the Royal College of
Pathologists, and the Academy of Medical Sciences (UK); a distinguished
fellow at the Hoover Institution, Stanford University; and a member of the
Council for Foreign Relations and the IOM Forum on Microbial Threats.
Mitchell D. Schnall, M.D., Ph.D., is an international leader in transla-
tional biomedical and imaging research, working throughout his career
across the interface between basic imaging science and clinical medicine to
ensure effective integration of radiology research with other medical disci-
plines. His work has led to fundamental changes in the imaging approaches
to breast and prostate cancer, and he continues to have a significant influ-
ence on emerging imaging technologies, including those in optical imaging.
Dr. Schnall was elected group chair of the American College of
Radiology Imaging Network (ACRIN) in 2008, after having served as its
deputy chair from 1999 through 2007. ACRIN is an NCI-sponsored cancer
cooperative group that designs, conducts, and reports on multicenter clini-
cal trials of imaging in cancer and conducts similar research in neurology
and cardiovascular studies through non-NCI funding. Among the multiple
ACRIN clinical studies under Dr. Schnall's direction are the National Lung
Screening Trial, the Digital Mammography Imaging Screening Trial, and
the National CT (computed tomography) Colonography Trial. Dr. Schnall
is co-PI of the Center for Magnetic Resonance and Optical Imaging, an
NIH-funded regional resource at the University of Pennsylvania.
Dr. Schnall maintains active membership in the American Society for
OCR for page 128
128 INFORMATICS NEEDS AND CHALLENGES IN CANCER RESEARCH
Clinical Investigation, the Association of American Physicians, ASCO, and
the Radiological Society of North America. He received his undergraduate,
medical, and doctoral degrees from the University of Pennsylvania, where
he has served on the faculty of the Radiology Department since 1991 and
as full professor since 2002.
Lawrence N. Shulman, M.D., is chief medical officer, senior vice presi-
dent for medical affairs, and chief, Division of General Oncology, Depart-
ment of Medical Oncology, at Dana-Farber Cancer Institute (DFCI). He
focuses his efforts on clinical services for both adult and pediatric care at
DCFI and its partners, Brigham and Women's Hospital and Children's
Hospital.
Dr. Shulman has served as one of the component leaders through the
DFCI strategic planning initiative. He is director of network development
for Dana-FarberBrigham and Women's Cancer Center and oversees DFCI
ambulatory oncology units at several regional sites. He is also physician
leader for the development of clinical information systems for DFCI.
He is chair of the ASCO Quality of Care Committee and a member of
ASCO's Health Information Technology Workgroup. He is also a member
of the ASCO Workgroup on Provider-Payer Initiatives. He is a member of
the Commission on Cancer of the American College of Surgeons and vice
chair of its Quality Integration Committee.
A specialist in the treatment of patients with breast cancer, his research
includes the development of new cancer therapies. He works closely with
Partners in Health, where he is senior adviser in oncology, helping to lead
the development of a structured cancer program for its resource-limited
health care sites in Rwanda, Malawi, and Haiti. He was the founding co-
chair, together with Dr. Julio Frenk, dean of the Harvard School of Public
Health, of the Global Task Force on Expanding Access to Cancer Care and
Control in the Developing World, a Harvard-based, international task force
committed to the improvement of cancer care worldwide.
PauPaul J. Wallace, M.D., is senior vice president and director, Center
for Comparative Effectiveness Research at The Lewin Group. Dr. Wallace
is a board-certified physician in internal medicine and hematology and
a researcher and lecturer on topics relating to comparative effectiveness
research (CER), including evidence-based medicine practice and policy,
performance improvement and measurement, clinical practice guideline
OCR for page 129
APPENDIX B 129
development; population-based care and disease management, new technol-
ogy assessment, and comparative assessment.
He has participated on several IOM advisory committees; he currently
serves as a member of the Board on Population Health and Public Health
Practice, and he chaired the committee that produced the recent report
Primary Care and Public Health: Exploring Integration to Improve Population
Health. He is vice chair of the board of directors for AcademyHealth and a
board member of the eHealth Initiative.
Dr. Wallace previously served on the National Advisory Committee
for AHRQ; the Medical Coverage Advisory Committee, Center for Medi-
care and Medicaid Services (CMS); and the Committee on Performance
Measurement for the National Committee on Quality Assurance (NCQA).
Before joining The Lewin Group in 2011, he was medical director for
health and productivity management programs at Kaiser Permanente's
national P ermanente Federation. He had served as a physician and admin-
istrator with Kaiser for more than 20 years. Prior to his work at Kaiser, he
taught clinical and basic sciences and investigated bone marrow function as
a faculty member at the Oregon Health Sciences University.
Dr. Wallace is a graduate of the University of Iowa School of Medicine
and completed further training in internal medicine, hematology, and can-
cer research at Strong Memorial Hospital and the University of Rochester.
OCR for page 130
